Kardigan Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Princeton Junction, New Jersey and currently employs 241 full-time employees. The company went IPO on 2026-06-18. Kardigan, Inc. is a clinical-stage precision therapeutics company. The company is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.